Free Trial

Viking Therapeutics Is Having a Year to Remember: Time to Buy?

Two apples, measuring tape, pills and notebook - stock image

Key Points

  • Viking Therapeutics Inc. has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.
  • The company’s weight management candidate, VK2735, showed significant weight loss in early trials and has attracted substantial interest from investors and analysts.
  • Viking offers compelling opportunities for risk-tolerant investors. Analysts predict up to 72.5% further upside and a promising pipeline, including its NASH treatment VK2809.
  • 5 stocks we like better than Viking Therapeutics.

Viking Therapeutics Today

Viking Therapeutics, Inc. stock logo
VKTXVKTX 90-day performance
Viking Therapeutics
$65.84
+3.39 (+5.43%)
(As of 10/11/2024 ET)
52-Week Range
$8.28
$99.41
Price Target
$108.60

Viking Therapeutics Inc. NASDAQ: VKTX, a clinical-stage biotechnology company with a market cap approaching $7 billion, is turning heads in 2024. Year to date, the stock has surged an impressive 238%, and its rise over the past 12 months has been even more dramatic, with shares climbing 326%.

For a mid-cap biotech, these kinds of gains significantly outpace both the broader market and its sector.

So, what’s driving Viking’s outperformance, and should investors on Main Street be paying attention?

What Is Viking Therapeutics?

Founded in 2012 and headquartered in San Diego, California, Viking Therapeutics is focused on developing novel therapies for metabolic and endocrine disorders. Their pipeline includes treatments targeting non-alcoholic steatohepatitis (NASH), hip fracture recovery, and type 2 diabetes. Viking's mission is to deliver life-changing treatments for patients with unmet medical needs, and its recent clinical success has captured the attention of Wall Street.

Why Has Wall Street Been Bullish on VKTX?

The stock’s notable surge started in February when Viking announced promising clinical trial results for VK2735, a dual GLP-1 and GIP receptor agonist being developed as a treatment for weight management. In its Phase 1 trial, patients who received VK2735 lost an average of 14.7% of their body weight after just 13 weeks of treatment, with weight loss continuing as the trial progressed. Viking is also working on an oral tablet version of the drug, currently in Phase 3 development.

The market for weight loss treatments has exploded in recent years, mainly due to the success of semaglutide, marketed by Novo Nordisk under the names Ozempic and Wegovy. Semaglutide is a GLP-1 drug, and its annualized sales reached nearly $28 billion in the second quarter of 2024. Viking's VK2735, which works on pathways similar to semaglutide, has drawn significant interest from investors and analysts who see it as a potential competitor in the growing weight-loss market.

Viking Therapeutics: More Than Just Weight Loss

While weight management has been a primary focus for Viking, it’s not the only promising aspect of the company’s pipeline. Viking's most advanced candidate, VK2809, has shown exceptional potential in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), previously known as NASH.

MASH affects millions of Americans by causing fat buildup in the liver, leading to inflammation and fibrosis. Viking recently reported that after 52 weeks of treatment, up to 75% of patients treated with VK2809 experienced resolution of MASH without worsening fibrosis, compared to just 29% in the placebo group. These results have positioned VK2809 as a strong candidate for addressing a condition lacking effective treatment options.

Analyst Love for VKTX

Viking Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™
94th Percentile
Analyst Rating
Buy
Upside/Downside
64.9% Upside
Short Interest Level
Healthy
Dividend Strength
N/A
Environmental Score
-0.88
News Sentiment
0.65mentions of Viking Therapeutics in the last 14 days
Insider Trading
Selling Shares
Proj. Earnings Growth
Decreasing
See Full Analysis

Viking’s recent success has not gone unnoticed by Wall Street analysts.

The stock currently boasts a Buy rating based on 11 analyst recommendations, with a consensus price target of $108.60, implying a further 72.5% upside from current levels.

Morgan Stanley recently reiterated its Overweight rating on VKTX, setting a price target of $105, reflecting a nearly 73% upside.

JPMorgan also initiated coverage in early September with an Overweight rating and a $80 price target, implying a 46% upside.

Should Risk-Tolerant Investors Consider Viking’s Weight-Loss Pipeline?

The biotech sector is known for its volatility. Still, Viking’s significant pipeline progress and its potential entry into the lucrative weight-loss drug market make it an intriguing candidate for investors with a higher risk tolerance. While the stock has already experienced triple-digit gains in 2024, analysts still forecast substantial upside.

Viking Therapeutics offers a compelling opportunity for those looking to gain exposure to an innovative biotech with significant momentum. With its VK2735 and VK2809 programs showing clinically solid results and Wall Street’s continued bullishness, VKTX could continue to deliver substantial returns to shareholders.

However, as with any investment in clinical-stage biotech, it’s important to remember the risks, including regulatory hurdles and competition. But for now, Viking Therapeutics remains a biotech success story that investors may want to keep on their radar.

Should you invest $1,000 in Viking Therapeutics right now?

Before you consider Viking Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.

While Viking Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Viking Therapeutics (VKTX)
4.6893 of 5 stars
$65.84+5.4%N/A-70.04Buy$108.60
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Recent Videos

Central Garden & Pet: Niche Focus, Big Growth Potential
Evolv Technologies Stock Up 59%: AI Security & 12-Month Forecast
Housing Prices Soar: These 3 Home Stocks May Benefit

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines